'Royal College of Obstetricians & Gynaecologists (RCOG)'
Abstract
The Editorial on the safety of vedolizumab by Sheridan and Doherty in response to our safety review is thoughtful and well balanced, but there are post-marketing data on malignancy after >25000 patient-years of experience with vedolizumab that they do not mentio